JP2014504601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504601A5 JP2014504601A5 JP2013550572A JP2013550572A JP2014504601A5 JP 2014504601 A5 JP2014504601 A5 JP 2014504601A5 JP 2013550572 A JP2013550572 A JP 2013550572A JP 2013550572 A JP2013550572 A JP 2013550572A JP 2014504601 A5 JP2014504601 A5 JP 2014504601A5
- Authority
- JP
- Japan
- Prior art keywords
- apolipoprotein
- pharmaceutical composition
- composition according
- biologically active
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161434196P | 2011-01-19 | 2011-01-19 | |
| US61/434,196 | 2011-01-19 | ||
| PCT/US2012/021802 WO2012100010A1 (en) | 2011-01-19 | 2012-01-19 | Apolipoprotein aiv as an antidiabetic peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014504601A JP2014504601A (ja) | 2014-02-24 |
| JP2014504601A5 true JP2014504601A5 (enExample) | 2015-04-23 |
Family
ID=45755499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550572A Pending JP2014504601A (ja) | 2011-01-19 | 2012-01-19 | 抗糖尿病ペプチドとしてのアポリポタンパク質ａｉｖ |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9051394B2 (enExample) |
| EP (1) | EP2665485B1 (enExample) |
| JP (1) | JP2014504601A (enExample) |
| KR (1) | KR20140071272A (enExample) |
| CN (1) | CN103391786B (enExample) |
| AU (1) | AU2012207301B2 (enExample) |
| CA (1) | CA2823712A1 (enExample) |
| EA (1) | EA028218B1 (enExample) |
| ES (1) | ES2620404T3 (enExample) |
| IL (1) | IL227207B (enExample) |
| MX (1) | MX342020B (enExample) |
| SG (1) | SG191992A1 (enExample) |
| WO (1) | WO2012100010A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010347724B2 (en) * | 2010-03-12 | 2016-06-23 | Exxonmobil Upstream Research Company | Dynamic grouping of domain objects via smart groups |
| SG191992A1 (en) | 2011-01-19 | 2013-08-30 | Univ Cincinnati | Apolipoprotein aiv as an antidiabetic peptide |
| EP2804618B1 (en) | 2012-01-19 | 2018-03-07 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| AU2013295721B2 (en) * | 2012-07-25 | 2017-07-20 | University Of Cincinnati | Method of treating type I diabetes using apolipoprotein AIV |
| WO2014018079A1 (en) * | 2012-07-25 | 2014-01-30 | University Of Cincinnati | Method of treating hyperglycemic disorders using apoliprotein aiv |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686605B1 (fr) * | 1992-01-27 | 1994-03-11 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides, leur preparation et leur utilisation. |
| AU7242394A (en) | 1993-05-28 | 1994-12-20 | Merck & Co., Inc. | Method to control appetite and treat obesity |
| WO2001077124A2 (en) * | 2000-04-05 | 2001-10-18 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the apoa4 gene |
| EP1556413A4 (en) * | 2002-05-17 | 2009-07-08 | Esperion Therapeutics Inc | METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION |
| US20100267052A1 (en) * | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| CA2719001A1 (en) | 2008-03-21 | 2009-09-24 | Podiceps B.V. | Diagnostic of pre-symptomatic metabolic syndrome |
| CN103788043B (zh) * | 2008-11-28 | 2016-02-03 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途 |
| SG191992A1 (en) | 2011-01-19 | 2013-08-30 | Univ Cincinnati | Apolipoprotein aiv as an antidiabetic peptide |
| EP2804618B1 (en) | 2012-01-19 | 2018-03-07 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| AU2013295721B2 (en) | 2012-07-25 | 2017-07-20 | University Of Cincinnati | Method of treating type I diabetes using apolipoprotein AIV |
| WO2014018079A1 (en) | 2012-07-25 | 2014-01-30 | University Of Cincinnati | Method of treating hyperglycemic disorders using apoliprotein aiv |
-
2012
- 2012-01-19 SG SG2013054358A patent/SG191992A1/en unknown
- 2012-01-19 MX MX2013008374A patent/MX342020B/es active IP Right Grant
- 2012-01-19 KR KR1020137020637A patent/KR20140071272A/ko not_active Ceased
- 2012-01-19 AU AU2012207301A patent/AU2012207301B2/en not_active Ceased
- 2012-01-19 JP JP2013550572A patent/JP2014504601A/ja active Pending
- 2012-01-19 CN CN201280005394.9A patent/CN103391786B/zh not_active Expired - Fee Related
- 2012-01-19 ES ES12705517.6T patent/ES2620404T3/es active Active
- 2012-01-19 EA EA201391063A patent/EA028218B1/ru not_active IP Right Cessation
- 2012-01-19 CA CA2823712A patent/CA2823712A1/en not_active Abandoned
- 2012-01-19 EP EP12705517.6A patent/EP2665485B1/en active Active
- 2012-01-19 US US13/980,749 patent/US9051394B2/en active Active
- 2012-01-19 WO PCT/US2012/021802 patent/WO2012100010A1/en not_active Ceased
-
2013
- 2013-06-26 IL IL227207A patent/IL227207B/en active IP Right Grant
-
2015
- 2015-05-05 US US14/704,418 patent/US9266941B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506942A5 (enExample) | ||
| JP2011241213A5 (enExample) | ||
| JP2014504601A5 (enExample) | ||
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP2014526441A5 (enExample) | ||
| JP2018138578A5 (enExample) | ||
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| JP2019196370A5 (enExample) | ||
| KR102357275B1 (ko) | 심부전을 치료하기 위한 뉴레귤린의 연장 방출 | |
| JP2016539921A5 (enExample) | ||
| JP2013507439A5 (enExample) | ||
| JP2008505919A5 (enExample) | ||
| ES2866957T3 (es) | Agente terapéutico del síndrome de Hunter y método de tratamiento | |
| TR201815158T4 (tr) | Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri. | |
| JP2015520188A5 (enExample) | ||
| JP2014513952A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| JP2014516088A5 (enExample) | ||
| JP2020502150A5 (enExample) | ||
| WO2015173427A2 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique | |
| BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| JP2014129405A5 (enExample) |